Tags : CROI

Clinical Trials

Gilead Presents Four-Year Data of Biktarvy for HIV-1 in Treatment-Naïve

Shots: The two OLE P-III 1489 and 1490 studies assessing Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg) vs dolutegravir-containing triple for the treatment of HIV-1 in treatment naïve adults The study demonstrated the sustained efficacy & safety profile with no treatment-emergent resistance @144wks, >98% of treatment-naïve patients achieved and maintained undetectable viral load […]Read More